Aseem Anand
Aseem Anand
Verifierad e-postadress på mskcc.org
Titel
Citeras av
Citeras av
År
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ...
The Lancet 375 (9724), 1437-1446, 2010
10502010
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
DC Danila, G Heller, GA Gignac, R Gonzalez-Espinoza, A Anand, ...
Clinical cancer research 13 (23), 7053-7058, 2007
6482007
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
DC Danila, MJ Morris, JS De Bono, CJ Ryan, SR Denmeade, MR Smith, ...
Journal of Clinical Oncology 28 (9), 1496, 2010
4842010
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
DR Shaffer, MA Leversha, DC Danila, O Lin, R Gonzalez-Espinoza, B Gu, ...
Clinical cancer research 13 (7), 2023-2029, 2007
3592007
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer
MA Leversha, J Han, Z Asgari, DC Danila, O Lin, R Gonzalez-Espinoza, ...
Clinical cancer research 15 (6), 2091-2097, 2009
2142009
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
DC Danila, A Anand, CC Sung, G Heller, MA Leversha, L Cao, H Lilja, ...
European urology 60 (5), 897-904, 2011
1822011
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and …
P Helo, AM Cronin, DC Danila, S Wenske, R Gonzalez-Espinoza, ...
Clinical chemistry 55 (4), 765-773, 2009
1312009
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC …
HI Scher, G Heller, A Molina, TS Kheoh, G Attard, J Moreira, SK Sandhu, ...
Journal of Clinical Oncology 29 (18_suppl), LBA4517-LBA4517, 2011
1272011
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
D Rathkopf, BY Wong, RW Ross, A Anand, E Tanaka, MM Woo, J Hu, ...
Cancer chemotherapy and pharmacology 66 (1), 181-189, 2010
1122010
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
RW Ross, MD Galsky, HI Scher, J Magidson, K Wassmann, GSM Lee, ...
The lancet oncology 13 (11), 1105-1113, 2012
872012
Androgen receptor expression is associated with prostate cancer‐specific survival in castrate patients with metastatic disease
MJ Donovan, I Osman, FM Khan, Y Vengrenyuk, P Capodieci, ...
BJU international 105 (4), 462-467, 2010
822010
Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival
DC Danila, A Anand, N Schultz, G Heller, M Wan, CC Sung, C Dai, ...
European urology 65 (6), 1191-1197, 2014
722014
Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)
HI Scher, TM Beer, CS Higano, M Taplin, E Efstathiou, A Anand, D Hung, ...
Journal of Clinical Oncology 27 (15_suppl), 5011-5011, 2009
652009
Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 …
HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ...
Lancet 375 (9724), 1437-1446, 2010
592010
Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy
DC Danila, DE Rathkopf, MJ Morris, SF Slovin, LH Schwartz, K Farmer, ...
Journal of Clinical Oncology 26 (15_suppl), 5019-5019, 2008
552008
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer
D Rathkopf, G Liu, MA Carducci, MA Eisenberger, A Anand, MJ Morris, ...
Clinical Cancer Research 17 (4), 880-887, 2011
432011
Analytic validation of the automated bone scan index as an imaging biomarker to standardize quantitative changes in bone scans of patients with metastatic prostate cancer
A Anand, MJ Morris, R Kaboteh, L Båth, M Sadik, P Gjertsson, M Lomsky, ...
Journal of Nuclear Medicine 57 (1), 41-45, 2016
422016
Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a …
AJ Armstrong, A Anand, L Edenbrandt, E Bondesson, A Bjartell, ...
JAMA oncology 4 (7), 944-951, 2018
322018
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide
A Anand, MJ Morris, SM Larson, D Minarik, A Josefsson, JT Helgstrand, ...
EJNMMI research 6 (1), 1-7, 2016
282016
Clinical Correlates of Benefit From Radium‐223 Therapy in Metastatic Castration Resistant Prostate Cancer
A Alva, L Nordquist, S Daignault, S George, J Ramos, C Albany, ...
The Prostate 77 (5), 479-488, 2017
252017
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20